甲氨蝶呤联用bDMARD不增加类风湿关节炎严重不良事件及严重感染风险:系统综述与荟萃分析
该系统综述与荟萃分析比较了类风湿关节炎(RA)中甲氨蝶呤联合bDMARD与bDMARD单药治疗的严重不良事件、严重感染及死亡风险。纳入16项随机对照试验,结果显示两组严重不良事件(RR 0.92, 95%CI 0.78-1.08)、严重感染(RR 1.15, 95%CI 0.84-1.58)及死亡(RR 0.73, 95%CI 0.40-1.35)风险均无显著差异,结核风险有升高趋势但无统计学意义(RR 1.78, 95%CI 0.63-4.99)。
要点
- 甲氨蝶呤联合bDMARD与bDMARD单药相比,严重不良事件风险无显著差异(RR 0.92, 95%CI 0.78-1.08)。
- 严重感染风险无显著差异(RR 1.15, 95%CI 0.84-1.58),死亡风险亦无显著差异(RR 0.73, 95%CI 0.40-1.35)。
- 结核风险有升高趋势但无统计学意义(RR 1.78, 95%CI 0.63-4.99)。
核心结论
- 在RA患者中,甲氨蝶呤联合bDMARD治疗与bDMARD单药治疗相比,不增加严重不良事件、严重感染或死亡风险。
研究设计与样本
- 系统文献综述检索PubMed、Embase和Cochrane Library数据库至2016年2月,纳入比较甲氨蝶呤联合bDMARD与bDMARD单药治疗RA的随机对照试验。
- 最终纳入16项对照试验,采用Mantel-Haenszel法进行荟萃分析。
主要发现
- 12项试验的荟萃分析显示,严重不良事件风险在单药与联合治疗组间相当(RR 0.92, 95%CI 0.78-1.08)。
- 13项试验的荟萃分析显示,严重感染风险无显著差异(RR 1.15, 95%CI 0.84-1.58)。
- 10项研究观察到结核风险有升高趋势但无统计学意义(RR 1.78, 95%CI 0.63-4.99)。
- 12项试验的荟萃分析显示,死亡风险在两组间相当(RR 0.73, 95%CI 0.40-1.35)。
关键数值与推荐
- 严重不良事件:12项试验,RR 0.92(95%CI 0.78-1.08)。
- 严重感染:13项试验,RR 1.15(95%CI 0.84-1.58)。
- 结核:10项研究,RR 1.78(95%CI 0.63-4.99)。
- 死亡:12项试验,RR 0.73(95%CI 0.40-1.35)。
临床怎么用
- 在RA治疗中,甲氨蝶呤与bDMARD联合使用不增加严重不良事件、严重感染或死亡风险,支持联合治疗的安全性。
- 对于结核风险,尽管无统计学意义,临床仍需保持警惕。
局限性
- 文献检索截止至2016年2月,可能未纳入此后发表的研究。
- 仅纳入随机对照试验,可能限制外推性。
- 结核风险分析基于10项研究,置信区间宽,需谨慎解读。
以上解读依据论文摘要(全文未开放获取或许可不允许翻译转载)。
原文
OBJECTIVES: To compare the risk of serious adverse events, serious infections and death caused by methotrexate and biological disease-modifying antirheumatic drug (bDMARD) combination therapy versus a bDMARD prescribed as monotherapy in rheumatoid arthritis (RA). METHODS: A systematic literature review was conducted until February 2016 in PubMed, Embase and Cochrane Library databases by selecting randomised controlled trials comparing methotrexate and bDMARD combination therapy to bDMARD monotherapy in RA. The meta-analysis compared the occurrence of (1) serious adverse events, (2) serious infections and (3) death among these groups by the Mantel-Haenszel method. RESULTS: The literature review selected 16 controlled trials comparing methotrexate and bDMARD combination therapy to bDMARD monotherapy. After meta-analysis comparing patients under monotherapy to those under combination therapy: (1) the risk of occurrence of serious adverse events was comparable in 12 trials: RR (95% CI) 0.92 (0.78 to 1.08). (2) No significant difference was observed in the risk of occurrence of serious infections in 13 trials: RR (95% CI) 1.15 (0.84 to 1.58). We noted a trend, although insignificant, towards a high risk of the occurrence of tuberculosis in 10 studies: RR (95% CI) 1.78 (0.63 to 4.99). (3) The risk of death was comparable in 12 trials: RR (95% CI) 0.73 (0.40 to 1.35). CONCLUSIONS: The results showed no significant difference between the two groups, confirming that the use of methotrexate and bDMARD combination therapy in RA does not cause an increased risk of serious adverse events or serious infections or death compared with bDMARD monotherapy.
引用
- Baradat C, Degboé Y, Constantin A, et al. No impact of concomitant methotrexate use on serious adverse event and serious infection risk in patients with rheumatoid arthritis treated with bDMARDs: a systematic literature review and meta-analysis. RMD Open. 2017. PMID: 28270933. doi:10.1136/rmdopen-2016-000352
供执业医师工作参考,不替代临床判断;数值与分级以指南原文为准。